# US 2012/0252720 A1 · Compositions for treatment of ear disorders and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252720 A1
- Document ID: US20120252720A1
- Status: Published application
- Kind: A1
- Application number: 13/437,680
- Filed: 2012-04-02
- Published: 2012-10-04
- Earliest claimed: 2003-12-12
- Assignees: Otic Pharma Ltd.
- Inventors: Eran Eilat
- Web page: https://patentgrep.com/patent/US20120252720A1

## CPC

- A61K 9/122: {Foams; Dry foams (edible foams A61K9/0056)}
- A61K 9/0046: {Ear}
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/00: Drugs for skeletal disorders
- A61P 23/00: Anaesthetics
- A61P 27/16: Otologicals
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compositions and methods useful for the treatment of ear disorders, administered to a treated ear in the form of a foam or a mousse. Administering a medicament in such forms will increase the residence time of the medicament in the ear canal, provide relatively uniform distribution of the composition, and can increase the penetration of the active pharmaceutical ingredient in the affected area, may release active substances slowly, enhance treatment effectiveness, increase compliance and is more convenient to use than currently available ear medications. The administration in the form of a foam or a mousse may preferably be provided as a metered dose, of a volume suitable to fill the ear canal.

## Claims

### Claim 1

A method for treating an ear disorder comprising administering to a subject in need of such treatment a pharmaceutical composition in the form of a foam or mousse, the pharmaceutical composition comprising at least one pharmaceutical agent and a pharmaceutically acceptable carrier, wherein the ear disorder is selected from the group consisting of an external ear disorder, a middle ear disorder and an inner ear disorder.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the at least one pharmaceutical agent is selected from the group consisting of antibiotic agents, steroidal and non-steroidal anti-inflammatory agents, anti-fungal agents, anesthetic agents, antibacterial agents, anti-viral agents, and a combination thereof.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the antibiotic agent is selected from the group consisting of ciprofloxacin, norfloxacin, ofloxacin, trovafloxacin, lomefloxacin, levofloxacin, enoxacin, moxifloxacin, sulfonamides, polymyxin, chloramphenicol, neomycin, paramomomycin, colistimethate, bacitracin, vancomycin, tetracyclines, rifampins, cycloserine, beta-lactams, cephalosporins, amikacin, gentamycin, tobramycin, streptomycin, netilmycin, kanamycin, and pharmaceutically acceptable derivatives thereof.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the antibiotic is ciprofloxacin or moxifloxacin.

### Claim 5 (depends on 2)

The method according to claim 2, wherein the steroidal anti-inflammatory agent is selected from the group consisting of betamethasone, betamethasone dipropionate, fluocinonide, fluocinoline acetonide, hydrocortisone, methylprednisolone, clobetasol, beclomethasone, dexamethasone, dexamethasone sodium phosphate, triamcinolone and pharmaceutically acceptable derivatives thereof.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the steroidal anti-inflammatory agent is dexamethasone or hydrocortisone.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the pharmaceutical composition comprises ciprofloxacin and dexamethasone or pharmaceutically acceptable derivatives thereof.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the pharmaceutical composition comprises ciprofloxacin and hydrocortisone or pharmaceutically acceptable derivatives thereof.

### Claim 9 (depends on 2)

The method according to claim 2, wherein the antifungal agent is selected from the group consisting of amphotericins, fluconazole, flucytosine, natamycin, miconazole, ketoconazole, amphotericin B, nystatin, cromolyn, lodoxamide, levocabastin, naphazolin, antazoline, pheniramimane and pharmaceutically acceptable derivatives thereof.

### Claim 10 (depends on 2)

The method according to claim 2, wherein the anesthetic agent is selected from the group consisting of benzocaine, benzyl benzoate, bupivacaine, calamine, chloroprocaine, chloroxylenol, cinchocaine, cocaine, dexivacaine, diamocaine, dibucaine, dyclonine, etidocaine, hexylcaine, ketamine, levobupivacaine, lidocaine, menthol, mepivacaine, oxethazaine, phenol, pramoxine, prilocalne, amethocaine, tetracaine, proparacaine, propoxycaine, pyrrocaine, resorcinol, risocaine, rodocaine, ropivacaine, tetracaine, and pharmaceutically acceptable derivatives thereof.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the ear disorder is selected from a middle ear disorder and an inner ear disorder.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the external ear disorder is selected from the group consisting of otitis externa, necrotizing external otitis, blockage of the ear canal, otomycosis, perichondritis, bullous myringitis, granular myringitis, otomycosis, herpes zoster oticus (Ramsey Hunt Syndrome), contact dermatitis, ear eczema, lacerations of the external canal, pilar (sebaceous) cysts, epidermal cysts, benign lesions, and malignant lesions.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the external ear disorder is otitis externa.

### Claim 14 (depends on 11)

The method according to claim 11, wherein the middle ear disorder is selected from the group consisting of acute otitis media, chronic otitis media, serous otitis media, acute suppurative otitis media, chronic suppurative otitis media, acute mastoiditis, chronic mastoiditis, adenoid hypertrophy, neoplasia, intratubal obstruction, middle ear obstruction, perforation of the tympanic membrane, cholesteatoma, tympanosclerosis, temporal bone fractures, barotrauma, glomus tumors, and malignant neoplasia.

### Claim 15 (depends on 11)

The method according to claim 11, wherein the inner ear disorder is selected from the group consisting of Meniere's disease, vertigo, hearing loss, tinnitus, temporal bone fracture, and auditory nerve tumors.

### Claim 16 (depends on 1)

The method according to claim 1, wherein the subject is human subject.

### Claim 17 (depends on 1)

The method according to claim 1, wherein the subject is a domestic animal.
